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A B S T R A C T
Osteogenic differentiation of multipotent mesenchymal stem cells (MSCs) plays a crucial role in bone remodeling. Nu-
merous studies have described the deleterious effect of iron overload on bone density and microarchitecture. Excess iron
decreases osteoblast activity, leading to impaired extracellular matrix (ECM) mineralization. Additionally, iron overload
facilitates osteoclast differentiation and bone resorption. These processes contribute to iron overload-associated bone loss.
In this study we investigated the effect of iron on osteogenic differentiation of human bone marrow MSCs (BMSCs), the
third player in bone remodeling.
We induced osteogenic differentiation of BMSCs in the presence or absence of iron (0–50 μmol/L) and examined
ECM mineralization, Ca content of the ECM, mRNA and protein expressions of the osteogenic transcription factor runt-
related transcription factor 2 (Runx2), and its targets osteocalcin (OCN) and alkaline phosphatase (ALP). Iron dose-de-
pendently attenuated ECM mineralization and decreased the expressions of Runx2 and OCN. Iron accomplished com-
plete inhibition of osteogenic differentiation of BMSCs at 50 μmol/L concentration. We demonstrated that in response
to iron BMSCs upregulated the expression of ferritin. Administration of exogenous ferritin mimicked the anti-osteogenic
effect of iron, and blocked the upregulation of Runx2, OCN and ALP. Iron overload in mice was associated with elevated
ferritin and decreased Runx2 mRNA levels in compact bone osteoprogenitor cells. The inhibitory effect of iron is spe-
cific toward osteogenic differentiation of MSCs as neither chondrogenesis nor adipogenesis were influenced by excess
iron. We concluded that iron and ferritin specifically inhibit osteogenic commitment and differentiation of BMSCs both
in vitro and in vivo.
© 2016 Published by Elsevier Ltd.
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1. Introduction
Mesenchymal stem cells (MSCs) are multipotent stromal cells,
with the capability to differentiate into various mesenchymal lineages,
including but not limited to osteoblasts, chondrocytes and adipocytes
[1]. Numerous signaling cascades were explored driving the commit-
ment, and differentiation of MSCs toward the different lineages [2].
Osteogenic differentiation of MSCs is driven by many secreted
differentiation factors, including transforming growth factor-beta 1,
fibroblast growth factor, bone morphogenetic protein, wingless pro
Abbreviations: ALP, alkaline phosphatase; BMP2, bone morphogenetic protein
2; BMSCs, bone marrow-derived mesenchymal stem cells; CM-
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teins, Indian hedgehog, which all converge on the master osteogenic
transcription factor, runt-related transcription factor 2 (Runx2) [3].
The crucial importance of Runx2 in osteogenic differentiation is high-
lighted by the finding, that Runx2 deficient mice completely lack
differentiated osteoblasts resulting impaired bone formation, and die
shortly after birth [4,5]. Runx2 regulates the transcription of the major
bone-specific proteins, such as osteocalcin (OCN), osteopontin, bone
sialoprotein, α1 type I collagen and alkaline phosphatase (ALP), those
expression is required for proper bone formation [6]. Recently, the
role of reactive oxygen species (ROS) in osteogenesis, as a common
denominator of the diverse osteogenic signaling pathways, has been
established [7]. Studies revealed that tightly regulated levels of ROS
are critical in osteogenic differentiation of MSCs [7].
Hemochromatosis, the accumulation of excess iron in the body
tissues, damages different organs, particularly the liver, the pancreas
and the heart. Several reports described low bone density, osteoporo-
sis and/or osteopenia in patients with different forms of hemochro-
matosis [8–11]. Supporting this notion, both pharmacological and ge-
netic provocation of iron overload was shown to be associated with
bone abnormalities in rodent models of hemochromatosis. For exam-
ple, intraperitoneal injection of ferric iron results in bone loss [12,13].
Additionally, a bone phenotype of osteoporosis with low bone mass
and alteration of the bone microarchitecture has been described in a
mouse model of genetic hemochromatosis [14]. Recently, hepcidin,
the liver-derived regulator of iron homeostasis has been also identi
http://dx.doi.org/10.1016/j.bbadis.2016.06.003
0925-4439/© 2016 Published by Elsevier Ltd.
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fied as a factor influencing bone physiology. Lack of hepcidin triggers
severe tissue iron overload that is associated with low bone mass, and
altered bone microarchitecture [15,16].
Excess iron generates oxidative stress, characterized by an increase
in the steady state level of ROS, which mediates cellular and tissue
damage, that is believed to be the major pathogenic factor in iron over-
load diseases [17]. To counteract with iron toxicity, excess iron is se-
questered by ferritin, the major iron storage molecule. Ferritin shell
is made up of 24 subunits of two types, heavy (H) and light (L), and
can accommodate as much as 4500 Fe3 + ions in a safe and bioavail-
able form [18,19]. The H subunit exhibits ferroxidase activity that pro-
motes oxidation of Fe2 + into Fe3 +, while the L subunit plays a role in
iron nucleation, and long-term iron storage [18,20]. The expression of
ferritin subunits are tightly regulated by iron, both the transcriptional
and translational levels [21–23].
Bone is an active tissue that is continuously being reshaped, in a
process called remodeling, in which osteoclasts resorb bone tissue,
whereas osteoblasts deposit new bone tissue. The cellular mechanism
behind the detrimental role of excess iron in bone physiology can be
the consequence of facilitated differentiation, and increased activity of
osteoclasts, or decreased activity of osteoblasts, or both. Iron has been
shown to facilitate osteoclast differentiation [24]. Also, osteoclast ac-
tivity is increased in thalassemia major patients, but this was found
to be rather associated with inflammation, than increased iron stores
[25]. Previously, we showed that iron potently inhibited matrix min-
eralization of mature osteoblasts [26]. Iron-mediated inhibition of os-
teoblast matrix mineralization relied on decreased phosphate uptake,
and the downregulation of Runx2, the osteoblast-specific transcription
factor and its target transcripts: OCN and ALP [26]. Ferritin, the iron-
regulated, iron-storage protein, mimicked the inhibitory effect of iron
on matrix mineralization of mature osteoblasts [26].
Osteoblasts derive from mesenchymal progenitor cells, which mi-
grate to the site of injury, proliferate and differentiate [27]. Osteogenic
potential of these bone marrow-derived MSCs (BMSCs) is of crucial
importance for proper remodeling and/or healing, which is highlighted
by the recent discovery, that osteoporosis is associated with low os-
teogenic potential of circulating MSCs [28]. This prompted us to ex-
amine the role of iron in MSC osteogenic commitment, and differenti-
ation.
2. Materials and methods
2.1. Materials
Unless otherwise specified all reagents were from Sigma-Aldrich
Co. (St. Louis, MO, USA).
2.2. Cell culture
Human BMSCs derived from 2 different adult donors of Caucasian
origin were obtained from ScienCell Research Laboratories (Carls-
bad, CA, USA). Cells were maintained in DMEM (high glucose),
containing 10% FBS (Gibco, Grand Island, NY, USA), 10,000 U/mL
penicillin, 10 mg/mL streptomycin, 25 μg/mL amphotericin B, and
1 mmol/L sodium pyruvate. Cells were grown to confluence, and used
from passages 4 through 7. Iron was introduced as ferrous sulfate. Fer-
ritin was introduced as holo-ferritin (Ft).
2.3. Mice
All experiments were performed in compliance with institutional
(Institutional Ethics Committee, University of Debrecen) and national
guidelines. Ten C57BL/6 mice (8–10 weeks old, male) were randomly
divided into two groups. The iron-overload group was injected in-
traperitoneally with iron-dextran (200 mg/kg body weight, 3-times,
every other day), while control mice were treated with PBS. Mice
were sacrificed with CO2 inhalation and perfused with 5 mL of ice-
cold PBS, tibia and femur were harvested for analysis.
2.4. Isolation of compact bone osteoprogenitor cells (OPCs)
OPCs were isolated from compact bones as described by Zhu et
al. [29]. Briefly, after harvesting and cleaning the tibia and femur, the
epiphyses were removed. To release bone marrow, bones were frag-
mented and agitated in a mortar containing ice cold PBS supplemented
with 2% FBS and 1 mmol/L EDTA. This washing step was repeated 5
times, and the bone-marrow free bones were digested in 0.25% Colla-
genase Type I (5 min, RT). Then the bones were chopped into 1–2 mm
pieces and digested for an additional 45 min at 37 °C. Finally the bone
chips were washed, and the obtained suspension was filtered through
a 70 μm cell strainer and centrifuged (300g, 10 min, RT). Harvested
cells were used to isolate RNA immediately.
2.5. Induction of osteogenic differentiation
At confluence, BMSCs were switched to osteogenic medium,
which was prepared by adding inorganic phosphate (Pi) (0–3 mmol/L)
and Ca at the form of CaCl2 (0–1.2 mmol/L) to the growth medium.
Both growth medium and osteogenic medium were changed in every
other day. Unless otherwise specified, we used an osteogenic medium
that was supplemented with 3 mmol/L Pi and 1.2 mmol/L Ca. Al-
ternatively, osteogenic differentiation was induced by dexamethasone
(0.1 μmol/L), ascorbic acid (50 μmol/L) and β-glycerol-phosphate
(2 mmol/L) for 14 days. When appropriate, cycloheximide (CHX)
was used to inhibit protein synthesis at a concentration of 10 μg/mL.
2.6. Induction of chondrogenic differentiation
To induce chondrogenic differentiation, BMSCs were cultured in
chondrogenic medium, containing StemPro Chondrogenesis Supple-
ment (Gibco, Grand Island, NY, USA) and gentamicin (10 mg/mL)
for 14 days.
2.7. Induction of adipogenic differentiation
To induce adipogenic differentiation, confluent BMSCs were cul-
tured in adipocyte differentiation medium, containing StemPro
Adipocyte Supplement (Gibco, Grand Island, NY, USA) and gentam-
icin (10 mg/mL) for 3 weeks.
2.8. Alizarin red staining
After washing with PBS, the cells were fixed in 4% paraformalde-
hyde and rinsed with deionized water thoroughly. Cells were stained
with Alizarin Red S solution (2%, pH 4.2) for 20 min at room temper-
ature. Excessive dye was removed by several washes in deionized wa-
ter. Extracellular Ca deposition was stained in red color using Alizarin
Red S dye.
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2.9. Alcian blue staining
Alcian blue staining was performed with NovaUltra Special Stain
Kit (IHC World, Ellicott City, MD, USA) according to the manufac-
turer's instructions.
2.10. Oil Red O staining
After washing with PBS, the cells were fixed in 4% paraformalde-
hyde and rinsed with deionized water thoroughly. Isopropanol (60%)
was added to the cells for 5 min, followed by the addition of Oil Red
O working solution (0.18% in 60% isopropanol) for 5 min. Excessive
dye was removed by several washes in water.
2.11. Quantification of Ca deposition
Cells grown on 96-well plates were washed twice with PBS, and
decalcified with HCl (0.6 mol/L) for 30 min at room temperature. Ca
content of the HCl supernatants was determined by QuantiChrome
Calcium Assay Kit (Gentaur, Kampenhout, Belgium). Following de-
calcification, cells were washed twice with PBS, and solubilized with
a solution of NaOH (0.1 mol/L) and sodium dodecyl sulfate (0.1%),
and protein content of samples were measured with BCA protein as-
say kit (Pierce Biotechnology, Rockford, IL, USA). Ca content of the
cells were normalized to protein content, and expressed as μg/mg pro-
tein.
2.12. Intracellular phosphate measurement
After 1 day of culture, cells were washed twice with PBS and solu-
bilized with 1% Triton-X100. Cell lysates were assayed for inorganic
phosphate using QuantiChrome Phosphate Assay Kit (Gentaur, Kam-
penhout, Belgium).
2.13. Quantification of OCN
For OCN detection, the ECM of cells grown on 6-well plates was
dissolved in 100 μL of EDTA (0.5 mol/L, pH 6.9). OCN content of the
EDTA-solubilized ECM samples was quantified by an enzyme-linked
immunosorbent assay (ELISA) (eBioscience, San Diego, CA, USA).
2.14. Measurement of ALP activity
Cells grown on 96-well plates were treated with osteogenic
medium for 7 days. Then cells were lysed and 35 μL cell lysate was
mixed with 130 μL of ALP Yellow Liquid Substrate. Formation of
p-nitrophenol was followed at 405 nm for 30 min at 37 °C. Maximum
slope of the kinetic curves was used for calculation of ALP activity
which was then normalized to protein content.
2.15. Cell viability assay
Cell viability was determined by the MTT assay as previously
described [30]. Briefly, cells were cultured and treated in 96-well
plates for the indicated time. Then cells were washed with PBS, and
100 μL of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bro-
mide (0.5 mg/mL) solution in HBSS was added. After a 4-hour incu-
bation the MTT solution was removed, formazan crystals were dis-
solved in 100 μL of DMSO and optical density was measured at
570 nm.
2.16. Quantitative RT-PCR
RNA was isolated from cells using TRIzol (RNA-STAT60, Tel-
Test Inc., Friendswood, TX, USA) according to the manufacturer's
protocol. Two micrograms of RNA were reverse transcribed to cDNA
with High-Capacity cDNA Reverse Transcription Kits (Applied
Biosystems, Waltham, MA, USA). Quantitative real-time PCR was
performed using iTaq Universal Probes Supermix (BioRad Laborato-
ries, Hercules, CA, USA) and predesigned primers and probes (Taq-
Man® Gene Expression Assays) to detect Fabp4 (fatty acid-bind-
ing protein 4) (Hs.391561), Runx2 (Hs.535845, Mm.00850707), FtH
(Mm.00501584), GAPDH (Mm.99999915) and HPRT (hypoxanthine-
guanine phosphoribosyl transferase) (Hs.412707). Relative mRNA
expressions were calculated with the ΔΔCt method using HPRT or
GAPDH as internal control.
2.17. Western blot
To evaluate protein expressions, cell lysates were run on 10%
SDS-PAGE. Western Blotting was performed with the use anti-Runx2
antibody and anti-human ferritin heavy (FtH) and light (FtL) chain an-
tibodies (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 1:200
dilution, anti-aggrecan and anti-fatty acid binding protein 4 (Fabp4)
antibodies (ProteinTech, Chicago. IL, USA), at 1:500 dilution, fol-
lowed by HRP-labeled anti rabbit IgG antibody (Amersham Bio-
sciences Corp., Piscataway, NJ, USA). Antigen-antibody complexes
were visualized with the horseradish peroxidase chemiluminescence
system (Amersham Biosciences Corp., Piscataway, NJ, USA). After
detection, the membranes were stripped and reprobed for GAPDH us-
ing anti-GAPDH antibody at a dilution of 1:1000 (Novus Biologicals,
Littleton, CO, USA). Results were quantified by using Alpha DigiDoc
RT (Alpha Innotech, San Leandro, CA, USA) quantification system.
2.18. Intracellular ROS measurement
ROS production was monitored by using the 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydro-fluorescein di-acetate, acetyl es-
ter (CM-H2DCFDA) assay (Life Technologies, Carlsbad, CA, USA).
After a 24-hour treatment cells were washed with PBS and loaded
with CM-H2DCFDA (10 μmol/L, 30 min, in the dark). Cells were
washed thoroughly and fluorescence intensity was measured in every
30 min for 3 h applying 488 nm excitation and 533 nm emission
wavelengths. In some experiments ROS was scavenged by N-acetyl
cysteine (NAC, 0.5 mmol/L).
2.19. Statistical analysis
Data are shown as mean ± S.D. Statistical analysis was performed
by ANOVA test followed by post hoc Newman-Keuls test for multi-
ple comparisons. A value of p < 0.05 was considered significant.
3. Results
3.1. Pi and Ca induce mineralization of BMSCs in a dose-dependent
manner
The mechanisms of BMSC osteogenic differentiation and VSMC
osteoblastic trans-differentiation shares similarities including common
triggers. First we tested whether Pi and Ca, the well-known and phys-
iologically relevant triggers of osteogenic trans-differentiation of
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VSMCs induce osteogenic differentiation of BMSCs. At confluence
growth media was supplemented with different concentrations of Pi
(0–3 mmol/L) and Ca (0–1.2 mmol/L) and cells were cultured for
5 days. Alizarin red staining revealed that while Pi and Ca alone did
not induce ECM mineralization, when these triggers were applied to-
gether a dose-dependent mineralization of the ECM occurred, sug-
gesting a synergistic effect of Pi and Ca in inducing ECM calcifica-
tion (Fig. 1A). We observed a slight but significant increase in the Ca
content of the ECM when the growth media was supplemented with
2 mmol/L Pi, and 0.6 mmol/L Ca (Fig. 1B). Higher concentrations of
Ca and Pi induced a more robust increase in the Ca content of ECM
(Fig. 1B). Importantly, these concentrations of Ca and Pi did not influ-
ence cell viability that was assessed by MTT assay (Fig. 1C). Based
on these results, we used an osteogenic medium supplemented with
3 mmol/L Pi and 1.2 mmol/L to induce osteogenic differentiation of
BMSCs throughout this paper. Because the active, cell-mediated na-
ture of ECM mineralization in VSMCs was questioned for decades,
we wanted to be sure that Pi and Ca-induced mineralization is a cell-
mediated process in BMSCs. To investigate this, we supplemented
the osteogenic medium with the protein synthesis inhibitor, CHX. We
found that CHX completely inhibited ECM mineralization, proving
that de novo protein synthesis is required for ECM mineralization and
Ca deposition in BMSCs (Fig. 1D).
3.2. Iron inhibits Pi and Ca-induced mineralization of BMSCs in a
dose-dependent manner
Previously we showed that iron inhibits osteoblast activity as well
as Pi-induced osteogenic trans-differentiation of VSMCs [26,31]. To
examine whether iron can inhibit Pi and Ca-induced osteogenic differ-
entiation of BMSCs, we cultured the cells in osteogenic medium in the
presence (1–50 μmol/L), or absence of iron. As revealed by alizarin
red staining, iron caused a dose-dependent attenuation of mineraliza-
tion, leading to complete inhibition at the concentration of 50 μmol/L
(Fig. 2A). Next, we examined the effect of iron on Ca content of the
ECM. Iron caused a dose-dependent decrease in the Ca content of the
ECM (Fig. 2B). At the concentration of 50 μmol/L, iron lowered Ca
content of the ECM of stimulated cells down to the level of non-stim-
ulated cells (Fig. 2B).
3.3. Iron down-regulates the expression of Runx2 and its downstream
target OCN and ALP
Runx2 is the master transcription factor of osteogenesis therefore
next we examined the effect of iron on the level of Runx2. Osteogenic
stimulation induced an about 1.6-fold increase in Runx2 mRNA level
that was attenuated by iron (Fig. 3A). Importantly, iron at the con-
centration of 50 μmol/L decreased the level of Runx2 mRNA down
to the level of unstimulated cells (Fig. 3A). Parallel with changes in
mRNA levels, osteogenic stimulation increased the protein expres-
sion of Runx2 by 1.6-fold (Fig. 3B). Iron inhibited osteogenic stim-
uli-induced upregulation of Runx2. Moreover, iron at the concen-
tration of 50 μmol/L decreased Runx2 protein expression well be-
low the Runx2 expression of control cells (Fig. 3B). Next, we de-
termined the level of OCN, a bone-specific protein which expression
is under the control of Runx2. Osteogenic stimulation robustly in-
creased OCN level of the ECM, which increase was attenuated by
iron, leading to complete inhibition at the concentration of 25 μmol/
L or higher (Fig. 3C). Next, we have checked whether the anti-os-
teogenic effect of iron is selective for Ca and Pi-induced osteogenic
differentiation of BMSCs or it is a more general inhibitor of osteoge-
nesis. We triggered osteogenic differentiation with a mixture of dex
Fig. 1. Pi and Ca induce mineralization of BMSCs in a dose-dependent man-
ner. Confluent BMSCs (passage 5–6) grown in 96-well plates were cultured in growth
medium supplemented with Pi (0–3 mmol/L) and Ca (0–1.2 mmol/L) as indicated for
5 days. (A) Ca deposition as a readout of ECM mineralization was visualized by alizarin
red staining. Representative image of stained plates from three independent experiments
is shown. (B) Ca content of HCl-solubilized ECM is shown. Data are expressed as
mean ± S.D. of three independent experiments performed in quadruplicates.*p < 0.05,
**p < 0.01, ***p < 0.005. (C) Cell viability was determined by MTT assay after 5 days
of osteogenic treatment. Data represent mean ± S.D. of three independent experiments
performed in quadruplicates. (D) Confluent BMSCs were cultured under control (Ctrl)
or osteogenic conditions (3 mmol/L Pi, and 1.2 mmol/L Ca) in the absence or presence
of cycloheximide (CHX, 10 μg/mL) for 5 days. Ca content of HCl-solubilized ECM
is shown. Results are expressed as mean ± S.D. of three independent experiments
performed in triplicates. ***p < 0.005.
amethasone, ascorbic acid and β-glycerolphosphate in the presence
or absence of iron (50 μmol/L). Osteogenic mixture induced a
3.4 ± 0.86-fold, and a 5.75 ± 1.27-fold increase in Runx2 mRNA
level on day7 and day14 respectively (Fig. 3D). In contrast, when os-
teogenic mixture was applied in the presence of iron, mRNA level of
Runx2 stayed on the level of unstimulated cells (Fig. 3D). Addition-
ally, we evaluated whether iron inhibits osteogenic mixture-induced
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Fig. 2. Iron inhibits Pi and Ca-induced mineralization of BMSCs in a dose-dependent
manner. (A–B) Confluent BMSCs (passage 4–6) were cultured under control (Ctrl) or
osteogenic conditions (3 mmol/L Pi, and 1.2 mmol/L Ca) in the absence or presence of
iron (0–50 μmol/L) for 5 days. (A) Ca deposition as a readout of ECM mineralization
was visualized by alizarin red staining. Representative image of stained plates from
three independent experiments is shown. (B) Ca content of HCl-solubilized ECM is
shown. Results are expressed as mean ± S.D. from three independent experiments
performed in triplicates.*p < 0.05, ***p < 0.005.
increase of ALP activity. Osteogenic mixture consisted of dexametha-
sone, ascorbic acid and β-glycerolphosphate induced a marked eleva-
tion of ALP activity (4.76 ± 0.36 vs. 16.59 ± 1.69 unit/mg protein) in
BMSCs. Increase of ALP activity triggered by osteogenic mixture was
reduced by about 40% in the presence of iron (Fig. 3E).
3.4. Ferritin mimics the effect of iron in inhibiting ECM
mineralization of BMSCs
Previously we found that iron inhibits VSMC osteogenic trans-
differentiation and osteoblast activity, via the induction of ferritin
[26,31]. Our next question was whether the induction of ferritin is re-
sponsible for the anti-osteogenic effect of iron in BMSCs. As expected
we found that iron induce a dose-dependent increase in both subunits
of ferritin, FtH and FtL (Fig. 4A). Then we challenged BMSCs with
osteogenic stimulation in the presence of ferritin at the concentrations
of 1 and 2 mg/mL. Alizarin red staining revealed that ferritin strongly
inhibited ECM mineralization of BMSCs (Fig. 4B). This result was
confirmed by measuring Ca content of the ECM (Fig. 4C).
3.5. Ferritin mimics the effect of iron in down-regulating Runx2,
OCN and ALP
To examine whether inhibition of ECM mineralization by ferritin
is associated with failed increase in the expression of Runx2 upon
osteogenic stimuli, we measured Runx2 mRNA and protein expres-
sions in BMSCs challenged with osteogenic medium in the presence
or absence of ferritin. Osteogenic stimuli induced an about 2-fold in-
crease in Runx2 mRNA levels when compared to control cells (Fig.
5A).This response was completely abrogated in the presence of fer-
ritin. Western blot analysis revealed that ferritin dose-dependently de-
creased the expression of Runx2 when compared to stimulated cells
(Fig. 5B). Expressions of osteoblast-specific proteins, OCN and ALP
are under the control of Runx2, therefore next we examined whether
down-regulation of Runx2 is associated with decreased protein lev-
els of these target genes in BMSCs under osteogenic stimulation.
We determined OCN levels in the solubilized ECM of BMSCs,
and found that OCN levels were very low in ferritin-treated sam-
ples (Fig. 5C). Comparison of ALP expressions in BMSCs under os-
teogenic conditions in the presence or absence of ferritin revealed that
ALP expression of ferritin-treated cells was about ten times lower than
in the absence of ferritin (Fig. 5D).
3.6. Anti-osteogenic effect of iron and ferritin is independent of
phosphate uptake
Phosphate uptake is critical in initiating Pi-mediated osteogenic
trans-differentiation of VSMC. To examine whether iron or ferritin in-
fluence BMSC phosphate uptake, we assessed intracellular phosphate
levels in unstimulated and stimulated cells, in the presence or absence
of iron and ferritin. Osteogenic stimuli increased intracellular Pi lev-
els of BMSCs about 1.5-fold over unstimulated cells (Fig. 6A). Impor-
tantly neither iron nor ferritin treatment influenced phosphate uptake
of BMSCs, suggesting that other mechanism(s) are behind the anti-os-
teogenic effect of both iron and ferritin (Fig. 6A).
3.7. Iron overload increase ROS production in BMSCs, but increased
ROS production is not responsible for impaired osteogenesis
Considering that iron is involved in ROS generation, and that ROS
are recognized as critical factor in osteogenic differentiation of BM-
SCs, next we examined the effect of osteogenic stimuli on ROS lev-
els in the presence or absence of iron and ferritin. We followed ROS
generation for 3 h in BMSCs after a 24-hour osteogenic stimulation.
Osteogenic stimulation decreased ROS generation when compared
to non-stimulated cells (Fig. 6B). Interestingly, both iron and fer-
ritin inhibited osteogenic stimuli-induced decrease in ROS generation
in BMSCs, which resulted that ROS productions in iron or ferritin-
treated stimulated cells were similar to that of non-calcifying control
cells (Fig. 6B). Then we applied the ROS scavenger NAC and looked
at whether osteogenic potential of iron-treated cells can be restored
by scavenging excess ROS. NAC at the dose of 0.5 mmol/L was able
to completely scavenge iron-mediated excessive production of ROS
(Fig. 6C). To see whether scavenging excess ROS in iron-treated BM-
SCs could restore osteogenic ability of BMSCs, we cultured cells in
osteogenic medium alone or in the presence of Fe (50 μmol/L) and
NAC (0.5 mmol/L) for 5 days. Alizarin red staining revealed that min-
eralization did not occur in the co-presence of Fe and NAC (Fig. 6D).
This finding was confirmed by measuring Ca content of the HCl-solu-
bilized ECM (Fig. 6E).
3.8. Iron overload downregulates the expression of Runx2 in OPCs in
vivo
To investigate whether excess iron reduce osteogenic potential of
OPCs in vivo, we induced iron-overload condition in C57BL/6 mice
and measured mRNA level of the key osteogenic transcription fac-
tor, Runx2 and the iron storage protein FtH in compact bone-de-
rived OPCs. As we expected iron overload caused a marked increase
(4.52 ± 2.07-fold) in FtH mRNA level, which was associated with a
60% decrease in Runx2 mRNA level in OPCs.
3.9. Iron does not influence either chondrogenic or adipogenic
differentiation of BMSCs
BMSCs are multipotent cells, with the ability to differentiate into
chondrocytes as well. To examine whether iron can influence chon-
drogenic differentiation, we cultured BMSCs in chondrogenic
medium, supplemented with iron for 14 days. As revealed by Alcian
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Fig. 3. Iron inhibits osteogenic stimuli-induced upregulation of Runx2 and OCN. (A–C) Confluent BMSCs (passage 6–7) grown in 6-well plates were treated with osteogenic
medium supplemented with iron at the indicated concentrations (0–50 μmol/L) for 5 days. (A) Runx2 mRNA levels were determined by real time RT-PCR. Results are presented as
mean ± S.D. of three independent experiments performed in triplicates. **p < 0.01, ***p < 0.005. (B) Representative Western blots from three independent experiments are shown.
Relative expressions of Runx2 normalized to GAPDH were determined by densitometric analysis. Graph shows mean ± S.D. of three independent experiments. (C) ECM of cells
was dissolved in 100 μL of EDTA, and OCN content of the obtained samples was quantified by an ELISA. Results are presented as mean ± S.D. of three independent experiments
performed in triplicates. ***p < 0.005. (D) Confluent BMSCs (passage 7) grown in 6-well plates were treated with osteogenic medium supplemented with dexamethasone (0.1 μmol/
L), ascorbic acid (50 μmol/L) and β-glycerol-phosphate (2 mmol/L) in the presence or absence of iron (50 μmol/L) for 1, 7 and 14 days. Runx2 mRNA levels were determined by real
time RT-PCR. Results are presented as mean ± S.D. of two independent experiments performed in triplicates. **p < 0.01, ***p < 0.005. (E) Confluent BMSCs (passage 7) grown in
96-well plates were treated with osteogenic medium supplemented with dexamethasone (0.1 μmol/L), ascorbic acid (50 μmol/L) and β-glycerol-phosphate (2 mmol/L) in the presence
or absence of iron (50 μmol/L) for 1, 7 days. ALP activity was determined by a colorimetric assay and normalized to protein content. Results are presented as mean ± S.D. of two
independent experiments performed in quadruplicates. **p < 0.01, ***p < 0.005.
blue staining, iron did not influence chondrogenic differentiation of
BMSCs (Fig. 7A). This was confirmed by the determination of the ex-
pression of aggrecan, a major component of ECM of cartilaginous tis-
sues. As shown by Western blot, iron treatment did not influence the
expression of aggrecan, suggesting that iron had no effect on chon-
drogenic lineage commitment of BMSCs (Fig. 7B). Finally, we ex-
amined the role of iron in the process of adipogenic differentiation of
MSCs. We cultured BMSCs in adipogenic medium, in the absence or
presence of iron for 33 days. As revealed by Oil Red O staining, iron
did not influence adipogenic potential of BMSCs (Fig. 7C). To fur-
ther confirm that iron has no effect on adipogenesis, we determined
mRNA and protein expressions of Fabp4, the adipocyte-specific pro-
tein (Fig. 7D–E). We found no effect of iron on Fabp4 mRNA and
protein expressions, suggesting that adipogenic lineage commitment
is maintained in the presence of iron.
4. Discussion
In this study we used BMSCs to examine the effect of iron in the
processes of osteogenic, chondrogenic and adipogenic differentiation.
Osteogenic commitment and differentiation of BMSCs has been stud
ied extensively using various stimulants including bone-morpho-
genetic proteins, dexamethasone, L-ascorbic acid 2-phosphate, and
β-glycerolphosphate; being the last three are the most widely used
supplements in osteogenic medium [32]. To induce osteogenic differ-
entiation of BMSCs here we applied Pi and Ca, the well-known and
pathophysiologically relevant triggers of osteoblastic trans-differenti-
ation of VSMC [33]. We found that the effects of elevated Pi and Ca
are synergistic, and when applied together, they caused a robust ECM
mineralization, characterized by increased Ca content, and alizarin
red-positivity. Mineralization of ECM is much faster in response to
Ca and Pi when compared to previously described inducers (5 days vs.
8–14 days), that could be a great advantage in bone tissue-engineering
approaches [34].
Many lines of evidence suggested a link between iron overload
and decreased bone mass. Excess iron accumulates in the bones of
individuals with hemochromatosis [35], and there is a long-known
association between hemochromatosis and low bone mineral density
[8–11]. In a study of iliac crest biopsies from 21 individuals with se-
vere osteoporosis iron bone concentration was evaluated and a sig-
nificant increase in iron content in cortical bone was found in osteo-
porotic patients vs. 12 controls [36]. Recently in a prospective cross-
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Fig. 4. Ferritin mimics the effect of iron in inhibiting mineralization of BMSCs. (A)
Confluent BMSCs (passage 4–5) grown in 6-well plates were treated with osteogenic
medium supplemented with iron at the indicated concentrations (0–50 μmol/L) for
5 days. Expressions of ferritin H (FtH) and L (FtL) chains were determined by Western
blot. Immunoblots were reprobed with GAPDH and are representative of three
independent experiments. (B–C) Confluent BMSCs (passage 4–5) grown in 96-well
plates were treated with osteogenic medium in the presence or absence of ferritin (1
and 2 mg/mL) for 5 days. (B) Ca deposition as a readout of ECM mineralization was
visualized by alizarin red staining. Representative image of stained plates from three
independent experiments is shown. (C) Ca content of HCl-solubilized ECM is shown.
Results are expressed as mean ± S.D. from three independent experiments performed in
triplicates. ***p < 0.005.
sectional study on 80 patients with beta thalassemia major and inter-
media, the authors found that both serum ferritin and heart iron load
were negatively correlated with bone mineral density [37]. Animal
models of iron overload also supported the deleterious effect of excess
iron on bone mineral density [12–14,16,38,39].
Bone is a dynamic, highly vascularized tissue with a unique re-
pair capacity to heal and remodel without scarring. The remodeling
process is orchestrated mainly by osteoclasts, responsible for bone re-
sorption, and osteoblasts that build up the new bone tissue [40]. Os-
teoclasts differentiate from mononuclear precursors [41], whereas os-
teoblasts derive from mesenchymal progenitor cells, which migrate to
the site of injury, proliferate and differentiate [27]. Considering the
complexity of bone remodeling, the deleterious effect of iron on bone
physiology can be multifactorial.
The receptor activator of nuclear factor-kappa B ligand (RANKL)/
osteoprotegerin (OPG) pathway is the dominant regulator of osteo-
clast proliferation and activation [42]. Iron has been shown to facil-
itate RANKL-induced osteoclast formation in both RAW264.7 cells
and bone marrow-derived macrophages in an oxidative stress-medi-
ated way [24]. Iron overload conditions are associated with elevated
RANKL/OPG [43], whereas the iron-chelating lactoferrin has been
shown to improve bone density via decreasing RANKL/OPG ratio
[44]. Besides its effect on osteoclast differentiation, iron dramati-
cally influences osteoblast metabolism. Ferric iron has been shown
to decrease proliferation and mineralization of MC3T3-E1 osteoblas
Fig. 5. Ferritin abrogates osteogenic stimuli-mediated up-regulation of Runx2, OCN
and ALP in BMSCs. Confluent BMSCs (passage 6–7) grown in 6-well plates were
treated with osteogenic medium in the presence or absence of ferritin as indicated for
5 days. (A) Relative Runx2 level normalized to HPRT was determined by quantitative
RT-PCR. Results are expressed as mean ± S.D. from three independent experiments
performed in triplicates. **p < 0.01. (B) Representative Western blots from three
independent experiments are shown. Relative expressions of Runx2 normalized to
GAPDH were determined by densitometric analysis. Graph shows mean ± S.D. of
three independent experiments. (C) ECM of cells was dissolved in 100 μL of EDTA,
and OCN was quantified by ELISA. Results are expressed as mean ± S.D. of three
independent experiments. ***p < 0.005. (D) Expression of ALP was determined by
Western blot from whole cell lysate. Representative Western blots from three
independent experiments are shown. Relative expressions of ALP normalized to
GAPDH were determined by densitometric analysis. Graph shows mean ± S.D. of three
independent experiments.
tic cells [45]. Moreover, Zarjou et al. showed that iron down-regulates
the expression of osteoblast-specific proteins, such as OCN and ALP,
as well as the expression of Runx2, the osteoblast-specific transcrip-
tion factor in human osteoblasts [26]. The same study highlighted the
crucial importance of ferritin in iron-mediated inhibition of osteoblast
function [26].
Osteoblasts originate from BMSCs, therefore BMSCs play a piv-
otal role in bone homeostasis. Recently it has been shown that the
number of circulating BMSCs was increased in osteoporotic patients
compared to controls, but the cells derived from osteoporotic patients
showed decreased osteogenic commitment and differentiation poten-
tial [28]. Here we demonstrated that iron is a potent inhibitor of os-
teogenic differentiation of BMSCs. Iron decreased osteogenic stimuli-
triggered ECM mineralization of BMSCs (Fig. 2). In response to os-
teogenic stimuli, BMSCs increase the expression of Runx2, the key
transcription factor involved in osteogenic differentiation. In the pres-
ence of iron this response was completely abrogated. Parallel with
Runx2, OCN expression and ALP activity were increased in miner-
alizing ECM, but osteogenic stimuli-triggered elevation of OCN ex-
pression and ALP activity were attenuated in the presence of iron
(Fig. 3). We also showed that ferritin mimicked the inhibitory effect
of iron in BMSC differentiation and mineralization (Figs. 4–5) simi-
larly to that was found in osteoblasts [26]. Additionally, in this work
we investigated the in vivo effect of iron on osteogenic potential of
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Fig. 6. Iron and ferritin have no effect on phosphate uptake but increase ROS production in BMSCs. (A–B) Confluent BMSCs (passage 6–7) grown in 96-well plates were treated
with growth medium or osteogenic medium in the presence or absence of iron (50 μmol/L) or ferritin (2 mg/mL) as indicated, for 24 h. (A) Intracellular phosphate content of cell
lysates was determined with phosphate assay kit, in triplicates. Results are shown as mean ± S.D. from one representative experiment of three. **p < 0.01. (B) ROS levels were
detected for 3 h in every 30 min in triplicates. Results are expressed as mean ± S.D. of three independent experiments.**p < 0.01, ***p < 0.005. (C–D) Confluent BMSCs (passage
7) grown in 96-well plates were treated with osteogenic medium in the presence of iron (50 μmol/L) and NAC (0.5 mmol/L) when labeled. (C) ROS generation was measured 90 min
post-stimulation in quadruplicates. Results are shown as mean ± S.D. from one representative experiment of two. **p < 0.01. (D) Ca deposition as a readout of ECM mineralization
was visualized by alizarin red staining on day5. Representative image of stained plates from three independent experiments is shown. (E) Ca content of HCl-solubilized ECM on day5
is shown. Results are expressed as mean ± S.D. from three independent experiments performed in triplicates. ***p < 0.005.
Fig. 7. Iron overload downregulates the expression of Runx2 in compact bone OPCs
in vivo. (A–B) C57BL/6 mice were treated with iron-dextran (200 mg/kg, n = 5) or
vehicle (PBS, n = 5) 3 times in every other day. Runx2 and FtH mRNA levels were
determined in compact bone-derived OPCs by real time RT-PCR using GAPDH as
internal control. Results are presented as mean ± SEM. **p < 0.01.
OPCs. We found that Runx2, the key osteogenic transcription factor
is markedly downregulated in compact bone OPCs in mice with sys-
temic iron overload (Fig. 7). Our results provide a novel mechanism
via which excess iron/ferritin could contribute to osteoporosis by im-
pairing osteogenic differentiation of BMSCs and OPCs.
Several lines of evidence suggested an inverse relationship be-
tween osteogenic and adipogenic differentiation of MSCs such that
signaling pathways that induce osteogenesis do so at the expense of
adipogenesis and the other way around [46]. Therefore we examined
the role of iron in adipogenic differentiation of BMSCs expecting that
iron may increase adipogenic potential of BMSCs. Interestingly, we
found that iron does not influence adipogenesis (Fig. 8), suggesting
that the iron/ferritin system is an exception to this rule. Additionally,
we described here that iron does not impair chondrogenic differentia-
tion of BMSCs (Fig. 8).
It is currently believed that tightly regulated levels of ROS are cru-
cial in promoting diverse signaling pathways, involved in a wide va-
riety of cellular functions, including differentiation process [7]. For
example, excess ROS production has found to be associated with de-
creased bone formation via the inhibition of diverse signaling path-
ways, including Wnt, FOXO and Hedgehog signaling in MSCs [7].
Moreover, resveratrol, a natural polyphenol antioxidant was shown to
promote osteogenic differentiation of murine pluripotent stem cells
[47]. Considering that excess iron is a well-known trigger of intra-
cellular ROS formation, we hypothesized that iron inhibits osteogenic
differentiation of BMSCs, via facilitating ROS production. We found
that osteogenic differentiation of BMSCs is accompanied by de-
creased generation of ROS. Additionally, our data revealed that anti-
osteogenic activity of iron was associated with increased ROS gener-
ation (Fig. 6). On the other hand scavenging excess ROS with NAC
could not restore osteogenic potential of iron-treated BMSCs, suggest-
ing that the elevated ROS is not the ultimate inhibitor of the osteogenic
differentiation process. Recently it has been shown that osteogenic
differentiation of MSCs is accompanied by metabolic changes, upreg-
ulation of antioxidant enzymes and a dramatic reduction of intracellu-
lar ROS formation [48]. Based on these data we cannot exclude that
the observed elevation of ROS production in iron-treated BMSCs is
a consequence and not the cause of arrested osteogenesis, which re-
mained to be elucidated in further studies.
Interestingly ferritin, the cytosolic iron storage molecule, mimic-
ked the anti-osteogenic effect of iron. Usually ferritin is considered as
an anti-oxidant molecule that can store iron in a redox inactive form,
and thus prevents the formation of ROS [49]. But under specific cir-
cumstances ferritin can behave as a pro-oxidant molecule. For exam
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Fig. 8. Chondrogenic and adipogenic differentiation potentials of BMSCs are main-
tained in the presence of iron. (A–B) Confluent BMSCs (passage 5–6) grown in 6-well
plates were cultured in chondrogenic medium supplemented with iron (0–50 μmol/L)
for 14 days. (A) Chondrogenic differentiation was visualized by Alcian blue staining.
Representative image of stained plates from three independent experiments is shown.
(B) Expression of aggrecan was determined by Western blot from whole cell lysate.
Immunoblots were reprobed with GAPDH and are representative of three independent
experiments. (C–E) Confluent BMSCs (passage 5–6) grown in 6-well plates were
cultured in adipogenic medium supplemented with iron (0–50 μmol/L) for 33 days.
(C) Adipogenic differentiation was visualized by Oil Red O staining. Representative
image of stained plates from three independent experiments is shown. (D) Relative
Fabp4 level normalized to HPRT was determined by quantitative RT-PCR. Results are
expressed as mean ± S.D. from three independent experiments performed in triplicates.
***p < 0.005. (E) Expression of Fabp4 was determined by Western blot from whole
cell lysate. Immunoblots were reprobed with GAPDH and are representative of three
independent experiments.
ple, artesunate, the anti-malarial drug with anti-tumor activity, was
shown to induce cell death via enhancing lysosomal degradation of
ferritin [50]. It is becoming accepted that ferritin can behave a pro-
oxidant manner when certain trigger molecules can liberate the se-
questered iron, or open the gated pores of ferritin [51]. We found ele-
vated ROS production in ferritin-treated BMSCs, suggesting that fer-
ritin behave in a pro-oxidant manner under osteogenic stimulation.
Further studies are needed to address whether osteogenic stimulation
is a condition in which lysosomal degradation of ferritin occurs.
In conclusion, our findings provide evidence that excess iron
specifically inhibits in vitro osteogenic differentiation of BMSCs,
via the down-regulation of the key osteogenic transcription factor,
Runx2, meanwhile chondrogenic and adipogenic differentiation po-
tentials of BMSCs are maintained. The anti-osteogenic effect of iron
is mimicked by exogenously administered ferritin. Importantly, iron
overload in mice was associated with increased FtH and decreased
Runx2 expressions in compact bone-derived OPCs, suggesting that
the described mechanism could have importance in pathological bone
loss in iron overload diseases.
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